<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304837</url>
  </required_header>
  <id_info>
    <org_study_id>BB-IND 11948</org_study_id>
    <nct_id>NCT00304837</nct_id>
  </id_info>
  <brief_title>VEGF Gene Transfer for Critical Limb Ischemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Losordo, Douglas, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Losordo, Douglas, M.D.</source>
  <brief_summary>
    <textblock>
      The purpose of this gene therapy study is to evaluate the safety and efficacy of&#xD;
      intramuscular gene transfer using Vascular Endothelial Growth Factor (VEGF) or placebo in&#xD;
      patients with moderate to high-risk Critical Limb Ischemia (a condition in which there is&#xD;
      poor blood circulation in the leg). This trial will assess whether VEGF improves rest pain&#xD;
      and/or heals ulcers in the legs of patients with peripheral artery disease (blockages in leg&#xD;
      arteries.)&#xD;
&#xD;
      VEGF is DNA, or genetic material that will be injected into the leg muscles on three separate&#xD;
      occasions, each 2 weeks apart. Once the DNA is in the leg, it directs the cells of the artery&#xD;
      wall to increase its production of VEGF, which has been shown to cause new blood vessels to&#xD;
      grow. This experimental therapy is designed to grow new blood vessels around blockages in the&#xD;
      leg arteries.&#xD;
&#xD;
      The total length of participation in this study is approximately 1 year and will require&#xD;
      approximately 8 clinic visits within that year. Following enrollment in the study, testing&#xD;
      may be done for cancer screening, blood work, physical exams, vascular testing and eye exams.&#xD;
      There is no charge for any testing or office visits required by the study.&#xD;
&#xD;
      This study has been approved by the Food and Drug Administration (FDA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">April 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <condition>Critical Limb Ischemia</condition>
  <condition>Ischemia</condition>
  <condition>Leg Ulcer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>pVGI.1 (VEGF-2)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be at least 21 years old&#xD;
&#xD;
          -  Have critical limb ischemia&#xD;
&#xD;
          -  Have severe blockages in at least one artery in the affected leg as demonstrated by an&#xD;
             angiogram&#xD;
&#xD;
          -  Have nonhealing leg ulcers and/ or have severe rest pain secondary to a severely&#xD;
             decreased blood flow&#xD;
&#xD;
          -  Agree to participate in follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have any evidence of malignant neoplasms (other than non-melanoma skin cancer or in&#xD;
             situ carcinoma) within the last 5 years&#xD;
&#xD;
          -  Be pregnant or lactating&#xD;
&#xD;
          -  Have a history of alcohol or drug abuse within 3 months of screening&#xD;
&#xD;
          -  Have advanced (Rutherford Category 6) critical limb ischemia, characterized by&#xD;
             extensive tissue loss or gangrene&#xD;
&#xD;
          -  Have osteomyelitis&#xD;
&#xD;
          -  Have undergone successful aortic or lower extremity surgery, angioplasty, or lumbar&#xD;
             sympathectomy within the 2 months preceding screening&#xD;
&#xD;
          -  Be a suitable candidate for surgical or endovascular revascularization in the limb in&#xD;
             which treatment is proposed&#xD;
&#xD;
          -  Subjects in whom arterial insufficiency in the lower extremity is the result of a&#xD;
             non-atherosclerotic disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Douglas W. Losordo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas St. Elizabeth's Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Minneapolis Heart Institute at Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>March 16, 2006</study_first_submitted>
  <study_first_submitted_qc>March 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2006</study_first_posted>
  <last_update_submitted>October 18, 2010</last_update_submitted>
  <last_update_submitted_qc>October 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2010</last_update_posted>
  <keyword>Nonhealing leg ulcers</keyword>
  <keyword>Ischemic rest pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

